NCT01684956UnknownPhase 2
Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Volunteers With Type 1 Diabetes
Massachusetts General Hospital1 site in 1 country20 target enrollmentStarted: August 1, 2012Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Aggregate mean difference in tmax between the delivery methods (the insulin and glucagon data will be evaluated separately)
Study Overview
Brief Summary
The investigators are doing this research study to find out if the type of needle used to administer them affects the speed with which insulin and glucagon get into the blood. The investigators will compare a traditional insulin needle to an injection device, called the MicronJet, that uses microneedles to deliver medication into the top layer of your skin.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 18 years or older with clinical type 1 diabetes for at least one year
- •Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting insulins including insulin aspart (Novolog), insulin lispro (Humalog), and insulin glulisine (Apidra).
- •Ability to consume a sufficient amount of carbohydrates over 2-3 hours to cover 5 units of rapid acting insulin
- •Stimulated C-peptide <0.1 nmol/L at 90 minutes after liquid mixed meal tolerance test.
Exclusion Criteria
- •Unable to provide informed consent
- •Unable to comply with study procedures
- •Current participation in another diabetes-related clinical trial other than one that is primarily observational in nature. Potential subjects enrolled in trails of passive monitoring equipment, such as continuous glucose monitors (CGMs), are not excluded
- •Inadequate venous access as determined by study nurse or physician at time of screening
- •Pregnancy
- •Hemoglobin less than 13.5 for men and less than 12 for women
- •History of pheochromocytoma (fractionated metanephrines will be tested in patients with history increasing the risk for a catecholamine secreting tumor to include episodic or treatment refractory hypertension defined as requiring 4 or more medications to achieve normotension, paroxysms of tachycardia, pallor, or headache, or personal or family history of MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease)
- •History of adverse reaction to glucagon (including allergy) besides nausea and vomiting
- •History of adrenal disease or tumor
- •Hypertension (blood pressure > 160/100 mm/Hg at screening or day of study visit
- •History of allergy to aspirin or any history of aspirin intolerance, including Reye's syndrome, or gastric ulcer or bleeding associated with salicylates.
- •Blood dyscrasia or bleeding diathesis, such as hemophilia, Von Willebrand's disorder, and idiopathic thrombocytopenic purpura (ITP)
- •Peptic Ulcer
Arms & Interventions
Intradermal first
Experimental
Intradermal injection experiment first, followed by subcutaneous injection experiment
Intervention: Intradermal injection (Procedure)
Intradermal first
Experimental
Intradermal injection experiment first, followed by subcutaneous injection experiment
Intervention: Subcutaneous injection (Procedure)
Subcutaneous first
Experimental
Subcutaneous injection experiment first, followed by intradermal injection experiment
Intervention: Subcutaneous injection (Procedure)
Subcutaneous first
Experimental
Subcutaneous injection experiment first, followed by intradermal injection experiment
Intervention: Intradermal injection (Procedure)
Outcomes
Primary Outcomes
Aggregate mean difference in tmax between the delivery methods (the insulin and glucagon data will be evaluated separately)
Time Frame: 1 day
Secondary Outcomes
- Aggregate mean difference in area under the curve (AUC) between methods(1 day)
- AUC of 0-1 hour (and by subtraction hours 1-5)(1 day)
- AUC of 0-2 hours (and by subtraction hours 2-5)(1 day)
- Time to 50% of Total AUC (or said another way, time to 50% exposure)(1 day)
- Difference in mean visual analog pain score between insulin and glucagon with subcutaneous injection(1 day)
- Aggregate mean difference in t1/2max between the methods(1 day visit)
- Fraction of subjects with difference in tmax between the methods of > 25%(1 day)
- Fraction of "dry" injections with no reflux of fluid from the injection site(1 day)
- Aggregate mean difference in Cmax between the methods(1 day)
- Difference in mean visual analog pain score between the two methods(1 day)
- Difference in mean visual analog pain score between insulin and glucagon with intradermal injection(1 day)
Investigators
Steven J. Russell, MD, PhD
Associate Professor
Massachusetts General Hospital
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Berinert P Study of Subcutaneous Versus Intravenous AdministrationHereditary AngioedemaNCT00748202Johann Wolfgang Goethe University Hospital24
Completed
Phase 3
Subcutaneous Versus Intravenous Morphine When Switching From Oral to Parenteral Route in Palliative Cancer PatientsPain CancerNCT05236647University Hospital, Akershus60
Completed
Phase 1
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular LymphomaLymphoma, FollicularNCT00930514Hoffmann-La Roche281
Terminated
Not Applicable
Evaluation of Pharmacokinetic / Pharmacodynamic and Tolerance Assessment of Dermal Administration of Beta-lactams in the ElderlyBeta-LactamsAged SubjectNCT02897648Fondation Hôpital Saint-Joseph2
Completed
Phase 1
A Trial Investigating the Influence of Injection Speed and Volume on the Perception of Subcutaneous Injection PainDiabetes MellitusNCT01937702Profil Institut für Stoffwechselforschung GmbH80